Correlation of the skin and/or eye toxicity grade secondary to Cetuximab or Panitumumab and
the SNP profile of the Epidermal Growth Factor Receptor (EGFR) domain III region.
Correlation of SNP profile with indicators of tumour response parameters, such as
radiological response, duration of response, time to progression (TTP), overall survival (OS)
time, incidence of non-dermatological adverse events.